Evidence map›Paper›PMID 40980106›Full record

ArticleFrontiers in drug safety and regulation2023

External Comparator Cohort studies - clarification of terminology.

Gerd Rippin, Joan Largent, Wilhelmina Elisabeth Hoogendoorn, Héctor Sanz, Jaclyn Bosco, Christina Mack

Abstract read
In one paragraph

Article in Frontiers in drug safety and regulation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gerd RippinIQVIA, Biostatistics, Frankfurt, Germany.
Joan LargentIQVIA, Epidemiology, Boston, CA, United States.
Wilhelmina Elisabeth HoogendoornIQVIA, Epidemiology, Amsterdam, Netherlands.
Héctor SanzIQVIA, Biostatistics, Barcelona, Spain.
Jaclyn BoscoIQVIA, Epidemiology, Boston, MA, United States.
Christina MackIQVIA, Epidemiology, Research Triangle Park, NC, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Though there is only one term for the gold standard of Randomized Controlled Trials the terminology used for controlled research involving external data is diverse. Common terms include External Comparator/Control Arm study, Externally Controlled Trial, Synthetic Control study and Historical Control study. The term Externally Controlled Trial was recently selected by the U.S. Food and Drug Administration (FDA) and is in line with the use case of a pivotal trial. It entails pre-specification of the external dataset and its analysis in the trial protocol, which produces the highest amount of transparency, which is an important aspect for maximum credibility. If this pre-specification did not occur, we advocate the term External Comparator Cohort study (or short External Comparator study), which is derived by scrutinizing the paired terms study/trial, control/comparator and arm/cohort. Furthermore, we propose an overall framework of nomenclature, which is generally applicable for research projects involving external data. Only a precise and consistent use of terminology will most effectively safeguard from unintended implications, inaccurate perceptions, and misguided mindsets.

Indexed as

External Comparator Arm studiesExternal Comparator Cohort studiesExternal Comparator studiesExternally Controlled TrialsHistorical Control studiesnomenclatureSynthetic Control studiesterminology

Identifiers

PMID40980106
PMCPMC12443080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.